Skip to main content

Advertisement

SpringerLink
Log in

Risk of liver-associated morbidity and mortality in a cohort of HIV and HBV coinfected Han Chinese

  • Clinical and Epidemiological Study
  • Published:
Infection Aims and scope Submit manuscript

Abstract

Objectives

To investigate the incidence and risk factors of liver-associated morbidity and mortality in Han Chinese patients with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) coinfection.

Methods

A retrospective study was conducted.

Results

Of the 255 subjects with HIV and HBV coinfection, 181 (71.0%) received lamivudine-based combined antiretroviral therapy (cART). Of the patients, 49/255 (19.2%) developed advanced liver diseases (ALDs) (during 5.2 years): 30 patients developed clinically overt cirrhosis, 10 developed hepatocellular carcinoma and 9 developed severe reactivation of a preexisting chronic hepatitis B. Baseline CD4+ cell count <200 cell/mm3 (P = 0.013, OR = 6.503), baseline alanine aminotransferase (ALT) elevation (P = 0.011, OR = 14.456), and longer cumulated time with detectable HIV RNA (P = 0.008, OR = 1.814) and HBV DNA (P = 0.014, OR = 1.536) were risk factors for ALDs development, while CD4+ cell count changes ≥150 cells/mm3 within 3 months (P = 0.039, OR = 0.049) and the use of lamivudine-based cART (P = 0.030, OR = 0.034) were protective against ALDs development.

Conclusions

ALDs was common among HIV and HBV coinfected Han Chinese patients. Lamivudine-based cART was beneficial in terms of sustained HBV viral suppression and resulted in less incidence of ALDs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Thio CL, Seaberg EC, Skolasky R Jr, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002;360:1921–6.

    Article  PubMed  Google Scholar 

  2. Kellerman SE, Hanson DL, McNaghten AD, et al. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis. 2003;188:571–7.

    Article  PubMed  Google Scholar 

  3. Park S, Kang K, Park J, et al. Clinical efficacy of AST/ALT ratio and platelet counts as predictors of degree of fibrosis in HBV infected patients without clinically evident liver cirrhosis. Korean J Gastroenterol. 2004;43:246–51.

    PubMed  Google Scholar 

  4. Rong-Rong Y, Xi-En G, Shi-Cheng G, et al. Interaction of hepatitis B and C viruses in patients infected with HIV. J AIDS 2008;48:491–492.

    Google Scholar 

  5. Sheng WH, Chen MY, Hsieh SM, et al. Impact of chronic hepatitis B virus (HBV) infection on outcomes of patients infected with HIV in an area where HBV infection is hyperendemic. Clin Infect Dis. 2004;38:1471–7.

    Article  PubMed  Google Scholar 

  6. Colin JF, Cazals-Hatem D, Loriot MA, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology. 1999;29:1306–10.

    Article  PubMed  CAS  Google Scholar 

  7. Bonacini M, Louie S, Bzowej N, et al. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS. 2004;18:2039–45.

    Article  PubMed  Google Scholar 

  8. Bagaglio S, Bianchi G, Danise A, et al. Longitudinal evaluation of occult Hepatitis B infection in HIV-1 infected individuals during highly active antiretroviral treatment interruption and after HAART resumption. Infection. 2011;39:121–6.

    Article  PubMed  CAS  Google Scholar 

  9. Morsica G, Ancarani F, Bagaglio S, et al. Occult hepatitis B virus infection in a cohort of HIV-positive patients: correlation with hepatitis C virus coinfection, virological and immunological features. Infection. 2009;37:445–9.

    Article  PubMed  CAS  Google Scholar 

  10. Matthews GV, Cooper DA, Dore GJ. Improvements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir. Antivir Ther. 2007;12:119–22.

    PubMed  CAS  Google Scholar 

  11. Meade CS, Wang J, Lin X, et al. Stress and coping in HIV-positive former plasma/blood donors in China: a test of cognitive appraisal theory. AIDS Behav. 2010;14:328–38.

    Article  PubMed  Google Scholar 

  12. Qian HZ, Vermund SH, Kaslow RA, et al. Co-infection with HIV and hepatitis C virus in former plasma/blood donors: challenge for patient care in rural China. AIDS. 2006;20:1429–35.

    Article  PubMed  Google Scholar 

  13. Peters MG. End-stage liver disease in HIV disease. Top HIV Med. 2009;17:124–8.

    PubMed  Google Scholar 

  14. Sellier P, Schnepf N, Jarrin I, et al. Description of liver disease in a cohort of HIV/HBV coinfected patients. J Clin Virol. 2010;47:13–7.

    Article  PubMed  CAS  Google Scholar 

  15. Salmon-Ceron D, Lewden C, Morlat P, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol. 2005;42:799–805.

    Article  PubMed  CAS  Google Scholar 

  16. Konopnicki D, Mocroft A, de Wit S, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the Euro SIDA cohort. AIDS. 2005;19:593–601.

    Article  PubMed  Google Scholar 

  17. Fang CT, Chen PJ, Chen MY, et al. Dynamics of plasma hepatitis B virus levels after highly active antiretroviral therapy in patients with HIV infection. J Hepatol. 2003;39:1028–35.

    Article  PubMed  CAS  Google Scholar 

  18. Puoti M, Cozzi-Lepri A, Arici C, et al. Impact of lamivudine on the risk of liver-related death in 2, 041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis. Antivir Ther. 2006;11:567–74.

    PubMed  CAS  Google Scholar 

Download references

Conflict of interest

There are no potential conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Infectious Diseases, Zhongnan Hospital of Wuhan University, Donghu Road 169, Wuchang, Wuhan, China

    R. Yang, X. Gui, Y. Xiong, S. Gao, Y. Zhang, L. Deng, K. Liang, Y. Yan & Y. Rong

Authors
  1. R. Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. X. Gui
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y. Xiong
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Y. Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. L. Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. K. Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Y. Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Y. Rong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to X. Gui.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yang, R., Gui, X., Xiong, Y. et al. Risk of liver-associated morbidity and mortality in a cohort of HIV and HBV coinfected Han Chinese. Infection 39, 427–431 (2011). https://doi.org/10.1007/s15010-011-0145-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15010-011-0145-1

Keywords

Search

Navigation